Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Medrxiv : the Preprint Server for Health Sciences
|
March 27, 2026
Comparative effectiveness of three linezolid management strategies for peripheral neuropathy during multidrug- or rifampicin-resistant tuberculosis treatment
Matthew L Romo, Allison LaHood, Carole D Mitnick, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 25, 2020
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
Molly F Franke, Palwasha Khan, Cathy Hewison, et al.
The Lancet. Global Health
|
December 15, 2022
Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study
Helena Huerga, Mathieu Bastard, Alex Vicent Lubega, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 31, 2024
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis
Chengbo Zeng, Miguel A Hernán, Letizia Trevisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Matthew Romo, Allison LaHood, Carole D Mitnick, et al.
The European Respiratory Journal
|
June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
Palwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Catherine Hewison, Uzma Khan, Mathieu Bastard, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 21, 2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
Letizia Trevisi, Miguel A Hernán, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 4, 2022
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
Helena Huerga, Uzma Khan, Mathieu Bastard, et al.
PLOS Global Public Health
|
April 28, 2023
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
Carly A Rodriguez, Sara Lodi, C Robert Horsburgh, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Medrxiv : the Preprint Server for Health Sciences
|
March 27, 2026
Comparative effectiveness of three linezolid management strategies for peripheral neuropathy during multidrug- or rifampicin-resistant tuberculosis treatment
Matthew L Romo, Allison LaHood, Carole D Mitnick, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 25, 2020
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
Molly F Franke, Palwasha Khan, Cathy Hewison, et al.
The Lancet. Global Health
|
December 15, 2022
Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study
Helena Huerga, Mathieu Bastard, Alex Vicent Lubega, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 31, 2024
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis
Chengbo Zeng, Miguel A Hernán, Letizia Trevisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Matthew Romo, Allison LaHood, Carole D Mitnick, et al.
The European Respiratory Journal
|
June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
Palwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Catherine Hewison, Uzma Khan, Mathieu Bastard, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 21, 2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
Letizia Trevisi, Miguel A Hernán, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 4, 2022
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
Helena Huerga, Uzma Khan, Mathieu Bastard, et al.
PLOS Global Public Health
|
April 28, 2023
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
Carly A Rodriguez, Sara Lodi, C Robert Horsburgh, et al.
Page
of 7